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Abstract
Background: Radiotherapy plays an important role in the multimodal treatment of breast cancer. The response of
a breast tumour to radiation depends not only on its innate radiosensitivity but also on tumour repopulation by
cells that have developed radioresistance. Development of effective cancer treatments will require further molecular
dissection of the processes that contribute to resistance.
Methods: Radioresistant cell lines were established by exposing MDA-MB-231, MCF-7 and ZR-751 parental cells to
increasing weekly doses of radiation. The development of radioresistance was evaluated through proliferation and
colony formation assays. Phenotypic characterisation included migration and invasion assays and
immunohistochemistry. Transcriptomic data were also generated for preliminary hypothesis generation involving
pathway-focused analyses.
Results: Proliferation and colony formation assays confirmed radioresistance. Radioresistant cells exhibited
enhanced migration and invasion, with evidence of epithelial-to-mesenchymal-transition. Significantly, acquisition of
radioresistance in MCF-7 and ZR-751 cell lines resulted in a loss of expression of both ERα and PgR and an increase
in EGFR expression; based on transcriptomic data they changed subtype classification from their parental luminal A
to HER2-overexpressing (MCF-7 RR) and normal-like (ZR-751 RR) subtypes, indicating the extent of phenotypic
changes and cellular plasticity involved in this process. Radioresistant cell lines derived from ER+ cells also showed
a shift from ER to EGFR signalling pathways with increased MAPK and PI3K activity.
Conclusions: This is the first study to date that extensively describes the development and characterisation of three
novel radioresistant breast cancer cell lines through both genetic and phenotypic analysis. More changes were
identified between parental cells and their radioresistant derivatives in the ER+ (MCF-7 and ZR-751) compared with
the ER- cell line (MDA-MB-231) model; however, multiple and likely interrelated mechanisms were identified that
may contribute to the development of acquired resistance to radiotherapy.
Keywords: Radioresistance, Breast cancer, Global gene analysis, ER and EGFR signalling, Characterisation of
radioresistant cell lines
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Background
Radiotherapy (RT) is a commonly used adjuvant treat-
ment modality for a variety of solid cancers. Up to 83% of
breast cancer patients benefit from radiotherapy either
with curative or palliative intent [1]. Multiple studies,
including 6 randomized control trials and subsequent
meta-analyses, have shown that breast conserving surgery
(BCS) followed by whole breast RT achieves survival rates
and long term local control equivalent to that seen with
mastectomy, with the added advantages of relatively mild
toxicity and good cosmetic outcome [2–4]. However, des-
pite the successful use of adjuvant RT in breast cancer,
some patients will still develop loco-regional recurrences
following the completion of a RT course. While tumour
recurrence following RT can be due to residual disease or
aggressive tumour biology, it can also be due to the sur-
vival of a population of cells that either have a greater
intrinsic resistance to RT (e.g. hypoxic or cancer stem
cells) or develop de novo resistance. These radioresistant
cells can then repopulate the tumour site leading to recur-
rence and treatment failure.
Improved understanding of the mechanisms underlying
acquired radioresistance and the development of strategies
to circumvent this clinical problem are required. Previous
studies have shown that multiple factors are implicated in
the development of radioresistance, including deregulated
signalling pathways (e.g. PI3K/AKT, NF- B), oncogenic
miRNA overproduction, enhanced DNA damage re-
sponses, the presence of cancer stem cells, epithelial-to-
mesenchymal transition (EMT) and alterations in cancer
metabolism, along with the effect of the tumour micro-
environment itself (including hypoxia) [5]. Many studies
focus on isolated pathways when investigating radioresis-
tance, but it is likely that these pathways are interrelated
in complex networks; for example, hypoxia can cause a
more undifferentiated cellular phenotype, characterised by
an increased expression of stem cell markers, which can
also affect the expression of genes and pathways control-
ling stemness, such as Oct4, Notch and EMT [6].
In comparison to the investigation of chemoresistance,
the mechanisms underlying radioresistance development
are poorly understood, partly due to a lack of radioresis-
tant model systems. The use of global approaches to in-
vestigate resistance mechanisms is gaining interest, as
this allows for the study of multiple pathways simultan-
eously and provides an overview of complex biological
systems and response to treatment [7]. In this study we
developed novel in vitro radioresistant cell lines from ER
positive (ER+) and ER negative (ER-) breast cancer cell
lines. Parental cell lines were chosen to represent differ-
ent molecular subtypes of breast cancer and included
MCF-7 and ZR-751 cell lines (ER+, PgR+, HER2-),
which are hormone-dependent, and the MDA-MB-231
cell line, which is triple negative (ER-, PgR-, HER2-)
and consequently hormone-independent. We undertook
genotypic, phenotypic and functional characterisation of
our radioresistant models, enabling us to corroborate our
findings at the gene, protein and functional levels. This
approach allowed us not only to identify differences be-
tween parental cells and their derived RR cell lines but
also between ER+ and ER- cell lines. To our knowledge,
our study is the first to develop a ZR-751 RR cell line and
use multicellular tumour spheroids derived from RR cells
in functional assays and immunohistochemical analysis.
Methods
Cell culture
Cell culture reagents were obtained from Gibco Thermo
Fisher Scientific (Paisley, UK), unless otherwise stated.
Human breast cancer cell lines ZR-751, MCF-7 and
MDA-MB-231 were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% foetal
calf serum (FCS), 50 Uml− 1 penicillin and 50mgml− 1
streptomycin and incubated at 37 °C in a humidified at-
mosphere with 5% CO2. Cell lines obtained from the
American Type Culture Collection (LGC Standards,
Teddington, UK) were authenticated by short tandem
repeat (STR) profiling performed at Health England
(Porton Down, Salisbury, UK). All cell line DNA samples
tested matched 9 of 9 tested core alleles in DNA from
known cell line samples confirming their identity. All ex-
periments were performed using cells, maintained at low
passage number from these frozen stocks.
Irradiation of cells and development of radioresistant
cell lines
Cells were irradiated using a Faxitron cabinet X-ray sys-
tem 43855D (Faxitron X-ray Corporation, IL, USA).
Radioresistant cell lines (MCF-7 RR, ZR-751 RR and
MDA-MB-231 RR) were developed from their respective
parental cell lines (MCF-7, ZR-751 and MDA-MB-231)
by weekly exposure to single fractions of radiation. An
initial dose of 2 Gy was followed by weekly incremental
doses of 0.5 Gy for 12 weeks. During this period cells re-
ceived a total radiation dose of 57 Gy. Cells were subse-
quently maintained with further weekly doses of 5 Gy.
Sulforhodamine B proliferation (SRB) assay
Cells were seeded into 96 well plates (500 cells/well) and
incubated for 24 h. Cells were drug-treated or exposed
to radiation and fixed between 24 and 144 h after treat-
ment by the addition of 50 μl cold 25% trichloracetic
acid (Sigma-Aldrich, UK) per well at 4 °C for 1 h. Plates
were washed in H2O and, when dry, 50 μl SRB dye
(0.4% SRB dissolved in 1% glacial acetic acid (VWR
International)) was added to each well and incubated
for 30 min. Plates were washed 4 times in 1% glacial
acetic acid and, when dry, 150 μl of 10 mM Tris-NaOH
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buffer (pH 10.5) was added to each well. The plates
were incubated on a shaker for 60 min. Optical density
was measured at 540 nm using a Biohit BP800 spectro-
photometer (Biohit Ltd., UK) and Wallac 1420 Manager
program (PerkinElmer, UK). The half maximal inhibi-
tory concentrations (IC50 values) were calculated using
the GraphPad prism 7 package.
Colony formation (CF) assay
Cells were seeded into 75mm plates (1 × 103 cells/plate)
and incubated for 24 h before radiation treatment. Once
visible colonies had formed (approximately 50 cells per
colony) in the untreated control group (approximately
10–14 days post-seeding) the plates were washed twice in
PBS before fixing the cells with the addition of 5ml of
1,9-dimethyl-methylene blue zinc chloride double salt
(Sigma-Aldrich, UK). After 45min the plates were washed
and allowed to air dry before colonies were counted. Ana-
lysis was performed by calculating plating efficiencies and
survival fractions for control and treatment plates [8].
Scratch (migratory) assays
Cells were seeded into 6 well plates at a density to achieve
100% confluence after 24 h. Scratch assays were performed
as previously described [9]. 0.1% serum-supplemented
media was added to each well. Phase contrast images of
the cell monolayer were captured (Axiovert DS100, × 5 ob-
jective) during migration up to a maximum of 48 h
post-scratch. At each time point the area devoid of migrat-
ing cells was calculated using FIJI software and expressed
as a % of the initial scratched area.
Formation of multicellular tumour spheroids (MTS)
A single cell suspension of each cell line from a T175 flask
(approximately 15 × 106 cells) was transferred to a spinner
flask (Cellcontrol Spinner Flask, Integra, Switzerland) con-
taining 100ml of routine DMEM and placed onto a mag-
netic stirrer platform (Cellspin, Integra, Switzerland). MTS
developed over 7 days in normal incubation conditions.
3D invasion assay using multicellular tumour spheroids
A single MTS was removed with 500 μl of collagen mix (ice
cold 0.1% filtered acetic acid, cell matrix type 1-A (Alpha-
labs), 0.22M NaOH (Sigma-Aldrich, UK), FCS and 10x
DMEM (Sigma-Aldrich, UK) at concentrations of 45, 25,
10, 10 and 10%, respectively) and placed into a 24 well
plate. Cultures were incubated for 1 h to allow polymerisa-
tion of collagen and 500 μl routine DMEM was then added
to each well. Phase contrast images were captured (Axio-
vert DS100, × 5 objective) at regular intervals up to 120 h
post-seeding. MTS invasion was measured using a FIJI
macro developed by Matthew Pearson (IGMM Advanced
Imaging Resource, University of Edinburgh) at each time
point and expressed as a % of the initial MTS area.
Assessment of the effects of radiation on pathway
activation
Cells were seeded into 75mm plates (1.0 × 106 cells/plate)
and incubated for 24 h. Cells were serum-starved for 2 h
and exposed to 2 Gy radiation before undergoing routine
lysis collection at 0, 5, 10 and 30min post-radiation. Ly-
sates were snap frozen on dry ice and stored at − 70 °C for
western blot analysis.
Protein isolation and detection
Whole cell lysates were prepared as previously described
[10] and protein concentration was determined using a
bicinchoninic acid (BCA) assay. Equal amounts of pro-
tein were separated by sodium dodecyl sulphate (SDS)
polyacrylamide gel electrophoresis and transferred to
Immobilon-P transfer membrane (Millipore). Ponceau S
solution was used to visualise protein bands and confirm
equal loading; membranes were blocked using Odyssey
Blocking Buffer (LI-COR Biosciences, UK) (1:1 with
PBS) for 1 h, before incubating overnight at 4 °C with
primary antibodies (Table 1). Signals were detected
using IRDye 800CW (Li-Cor, 926–32,210, 1:10,000)
and IRDye 680LT (Li-Cor 926–68,021, 1:10,000) with
a Li-Cor Odyssey Imager. Membranes required for
re-probing were stripped using NewBlot PVDF Strip-
ping Buffer (LI-COR Biosciences, UK).
Immunohistochemistry (IHC) and immunocytochemistry
(ICC)
IHC was carried out on formalin-fixed MTS. Samples
were deparaffinised and rehydrated, and antigens re-
trieved (Table 1). Endogenous peroxidase activity was
inhibited with 3% H2O2 solution (Dako, UK) for 10 min
and non-specific antibody staining was blocked using
Total Protein Block (Dako, UK) for 10 min. Primary
antibodies were incubated for 1 h (Table 1). 1 drop of
Envision labelled polymer (Dako, UK) was added for 30
min, before DAB and substrate buffer (1:50) (Dako, UK)
were added to each section for 10 min.
ICC was performed on cells grown in chamber slides
(2 well chamber slide, Lab-Tek II, Scientific Laboratory
Supplies, UK) seeded to achieve a confluency of approxi-
mately 80% at 24 h. Cells were fixed in cold acetone
(500 μl/chamber) for 10 min at 4 °C, then washed twice
in PBS for 10 min. The same protocol as described for
MTS IHC, from the addition of H2O2 solution, was then
followed.
All slides were counterstained in haematoxylin, dehy-
drated and mounted with coverslips using DXP mount-
ant (Sigma-Aldrich, UK). Slides were scanned using a
NanoZoomer ER slide scanner (Hamamatsu Photonics,
UK) and viewed using NanoZoomer Digital Pathology
software.
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siRNA transfection
Cells were seeded into 96 or 6 well plates (500 or 2 × 105
cells per well, respectively) in media without antibi-
otics and incubated overnight to achieve 30–50% con-
fluence. Cells were transfected according to the
manufacturer’s protocol using DharmaFECT 1 Trans-
fection Reagent (Dharmacon) with on-target plus ERα
siRNA (J-103401-12) (GE Healthcare Dharmacon) at a
concentration of 25 nM.
RNA extraction and whole-transcriptome gene expression
analysis
Cells were seeded into 75mm plates (3.0 × 106 cells/
plate) and incubated for 24 h. Cells were serum-starved
for 2 h and were then exposed to either 0 or 2 Gy radi-
ation. Pellets of up to 1 × 107 cells were collected by
trypsinisation at 0, 2 and 8 h post-radiation, snap-frozen
on dry ice and stored at − 70 °C for subsequent RNA
extraction. Total RNA was extracted from cells with the
RNeasy Mini Kit using QIAshredder technology (UK Qia-
gen, Ltd). The manufacturer’s protocol for purification of
total RNA from animal cells using spin technology was
followed. Extracted RNA samples were quantified and
assessed for the presence of contaminants using the
NanoDropTM Spectrophotometer ND1000 (Thermo Fi-
scher Scientific). Full genome expression read-counts were
generated using Lexogen QuantSeq 3′ FWD sequencing
technology on an Illumina flow cell which was scanned
using an Illumina HiScanSQ system (Edinburgh Clinical
Research Facility, University of Edinburgh). NGS reads
were generated towards the poly(A) tail and read 1 dir-
ectly reflects the mRNA sequence. The ZR-751 2 h, 2 Gy
sample failed sequencing and was removed from further
analysis. RNA integrity number (RIN) was generated for
each sample to assess RNA quality (Agilent Bioanalyzer);
all samples had RIN values above 9.7 (Additional file 1:
Table S1). FASTQ files of raw read-count data were
pre-processed using the Lexogen recommended BlueBee
high-performance NGS analysis software which imple-
mented poly(A) tail trimming and alignment to the Gen-
ome Reference Consortium Human genome build 38
reference genome using the Spliced Transcripts Align-
ment to a Reference (STAR) algorithm [11]. Prior to ana-
lysis, data were log2 transformed and quantile normalised
in R (Bioconductor) software and packages [12]. These
preliminary transcriptomic data were only used for super-
vised pathway-focused analyses for the purposes of hy-
pothesis generation and each analysis was subsequently
validated by lab-based experimentation. Heatmap and
cluster analysis were performed using TM4 MeV (multiple
experiment viewer) software [13]. Heatmap clustering was
carried out using Pearson correlation with average linkage.
For integration of gene expression data with public data-
sets correction for integration batch effects was performed
in R using ComBat as described previously [14, 15].
Hierarchical clustering of parental and RR cell lines was
performed using a published list of genes whose expres-
sion profile denotes the breast cancer intrinsic subtypes
(basal, normal-like, Her2, luminal A and luminal B) [16].
Assignment of individual samples to intrinsic subtypes
was performed using the genefu R package [17]. Genefu
implements a Single Sample Predictor (SSP) algorithm
which is a nearest-centroid classifier. The centroids repre-
senting the breast cancer molecular subtypes were identi-
fied through hierarchical clustering using the same
intrinsic gene list that we used for cluster analysis in this
Table 1 Primary antibodies used for western blotting (WB), immunocytochemistry (ICC) and immunohistochemistry (IHC)
Primary antibody target antigen Antibody Details Dilutions and applications Antigen retrieval
Anti-α tubulin Mouse MAb; Abcam; ab7291 1:10,000 (WB) N/A
Anti-ERα Mouse MAb; Dako; M7047 1:50 (WB, ICC, IHC) Sodium citrate
Anti-EGFR Rabbit MAb; Cell Signalling Technology; 4267 1:1000 (WB); 1:50 (ICC, IHC) EDTA
Anti-HER2 Rabbit MAb; Cell signalling Technology; 2242 1:1000 (WB); 1:50 (ICC, IHC) Sodium citrate
Anti-PgR (A/B) Rabbit MAb; Cell Signalling Technology; 8757 1:1000 (WB) N/A
Anti-PgR Mouse Mab; DAKO; M3569 1:150 (ICC, IHC) EDTA
Anti-AKT Mouse MAb; Cell Signalling technology; 2920 1:1000 (WB) N/A
Anti-Phospho AKT Rabbit PAb; Cell Signalling technology; 9271 1:1000 (WB) N/A
Anti-ERK Rabbit PAb; Cell Signalling Technology; 9102 1:1000 (WB) N/A
Anti-Phospho ERK Mouse MAb; Cell Signalling Technology; 9106 1:1000 (WB) N/A
Anti-ki67 Mouse MAb; DAKO; M7240 1:150 (ICC, IHC) Sodium citrate
Anti-E-cadherin Mouse MAb; BD Transduction; 610,182 1:50 (ICC, IHC) Sodium citrate
Anti-N-cadherin Mouse MAb; BD Transduction; 610,921 1:150 (ICC, IHC) Sodium citrate
Anti-vimentin Mouse Mab; Abcam; 8069 1:50 (ICC, IHC) Sodium citrate
Anti-SNAIL Rabbit PAb; Abcam; 128,530 1:250 (ICC, IHC) Sodium citrate
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study. All datasets generated and/or analysed during the
current study are available in the NCBI’s Gene Expression
Omnibus [18] and are accessible through GEO Series
accession number GSE120798.
Immunohistochemistry and statistical analysis
Image analysis software QuPath version 0.1.2 [19] was
used to analyse ki67 and ERα target protein expression.
Two-way ANOVA with Holm-Sidak’s multiple compari-
sons test was used to test for differences between 2
groups in CF, SRB, invasion and migration assays and
western blot experiments. Unpaired (two tailed) t-test
was used to assess differences between 2 groups in IHC
analysis. P values < 0.05 were deemed statistically signifi-
cant. Data is shown as mean ± SEM with all statistical
analysis and graphs generated with GraphPad Prism
7. An overview of the samples included in each ex-
periment (including cell line, time points, treatments
and number of replicates) is provided in Additional
file 2: Table S2.
Results
Development and confirmation of the acquisition of
radioresistance in ER+ and ER- breast cancer cell lines
Radioresistant cell lines (MCF-7 RR, ZR-751 RR and
MDA-MB-231 RR) were developed from their parental
cell lines (MCF-7, ZR-751 and MDA-MB-231) by weekly
exposure to single fractions of radiation, increasing by 0.5
Gy per week over a period of 12 weeks; cells were subse-
quently maintained by weekly doses of 5 Gy. Although
maintenance radiation doses were still accompanied by
cell death in all 3 RR cell lines, this was significantly less
than that seen during the initial 12 week development
period. Radioresistance was confirmed by both CF and
SRB assays. The CF ability of all RR cell lines was signifi-
cantly higher than their respective parental cell lines when
exposed to a single dose of radiation up to 6Gy (Fig. 1a).
Significantly less inhibition of proliferation was also seen
in the RR cell lines compared to their parental cell lines
when exposed to a single dose of radiation up to 10 Gy
(Fig. 1b). The IC50 (the dose of radiation required to re-
duce cell number by 50%) values were higher in the RR
cell lines when compared to their parental cells (Table 2).
MCF-7 RR and MCF-7 RR cells which had not received
radiation for 6months (MCF-7 rr) were similarly radiore-
sistant (Additional file 3: Figure S1), suggesting the longev-
ity of the changes involved in the acquisition of this
phenotype.
Radioresistant cell lines have concurrent lower expression
of cell cycle associated genes and modified basal
proliferation rates relative to their parental cells
SRB assays were used initially to assess proliferation
rates in 2D cultures (Fig. 2a). Results showed lower rates
Fig. 1 Confirmation of radioresistance using colony formation and SRB assays. a Colony formation assays comparing MCF-7 RR, ZR-751 RR
and MDA-MB-231 RR cell lines with their respective parental cell lines. b SRB proliferation assays comparing MCF-7 RR, ZR-751 RR and
MDA-MB-231 RR with their respective parental cell lines (2-way ANOVA with Holm-Sidak’s multiple comparisons test; data expressed as
mean ± SEM, n = 3, ****p ≤ 0.0001; ***p ≤ 0.001; *p ≤ 0.05)
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Table 2 Table of IC50 values for each parental and RR cell line up to 144 h post-exposure to radiation. If no value is recorded this
indicates that a reduction in proliferation by 50% at that time point had not occurred; MCF-7 and MDA-MB-231 cell lines were
evaluated up to 120 h post radiation whereas ZR-751 cell line was evaluated up to 144 h post radiation
Time Post Radiation (h) MCF-7 MCF-7 RR ZR-75-1 ZR-75-1 RR MDA-MB-231 MDA-MB-231 RR
24 – – – – – –
48 – – – – – –
72 4.98 9.64 – – – –
96 3.27 5.36 – – 3.53 9.71
120 3.74 5.22 – – 3.13 7.11
144 N/A N/A 4.38 6.91 N/A N/A
Fig. 2 Radioresistant cell lines have modified basal proliferation rates relative to their parental cells. a SRB assays showing differences in
proliferation rates between parental and RR cell lines grown in 2D cultures (2-way ANOVA with Holm-Sidak’s multiple comparisons test). b IHC of
MTS stained for ki67 using MCF-7 and ZR-751 parental and RR cell lines with quantitative analysis of the % of positively stained cells (unpaired,
two tailed t-test) (data expressed as mean ± SEM, n = 3, ****p ≤ 0.0001; ***p ≤ 0.001; *p ≤ 0.05). c Heatmap showing log2 mean-centered gene
expression profiles of proliferation genes in parental and RR cell lines taken from the KEGG database cell cycle pathway; red = higher expression,
green = lower expression. Heatmap clustering was carried out using Pearson correlation with average linkage
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of proliferation in the MCF-7 RR and MDA-MB-231 RR
and higher rates in the ZR-751 RR cell lines in compari-
son to their respective parental cell lines. Further investi-
gation of proliferation was performed through 3D assays
using IHC staining for the proliferation marker Ki67 in
MCF-7 and ZR-751 parental and RR MTS (Fig. 2b)
(MDA-MB-231 cell lines failed to develop MTS which
could withstand IHC processing). IHC with quantitative
analysis showed a lower percentage of positively stained
ki67 cells in the RR MTS suggesting lower basal prolifer-
ation rates than their parental cell lines. Using gene
expression data from 2D cultures, MCF-7 RR and
ZR-751 RR cell lines were characterised by lower expres-
sion of genes involved in DNA replication and repair
and those related to G1/S-phase transition and regula-
tion of cell cycle, including AURKA and TP53, along
with the higher expression of cell cycle arrest genes.
Fewer changes in these genes were identified in the
triple negative MDA-MB-231 parental and RR cell lines,
both of which clustered next to each other and the
MCF-7 and ZR-751 parental cell lines (Fig. 2c).
Radioresistant cell lines have increased invasion and
migration potential
Epithelial-to-mesenchymal transition (EMT) is considered
a normal feature of embryogenesis involved with cellular
movement and morphogenesis during embryonic develop-
ment [20] and may be an inherent property of normal basal
stem cells in the breast [21]. However, the process can also
be involved in tumour development with the conversion of
early stage non-invasive tumours into invasive malignan-
cies [22]. Acquisition of an EMT phenotype is associated
with increased migration and invasion potential. Here,
using a 3D invasion assay, we showed that both MCF-7 RR
and ZR-751 RR have increased invasive potential compared
to parental cells (which demonstrated little or no invasive
capabilities); although the MDA-MB-231 RR cell line
showed a slight increase in invasiveness at 72 h, this was
not statistically significant (Fig. 3a). Similarly, we assayed
for migration potential using a 2D scratch assay and
showed that all 3 RR cell lines had significantly enhanced
migratory ability compared to their parental cells (Fig. 3b).
Parental ER+ cell lines exhibited a typical epithelial-like
morphology, consisting of tightly packed cells forming
cobblestone-like monolayers, with the cells consisting of a
large nucleus and small amount of cytoplasm. By 12 weeks
post-radiation, morphological changes were observed in
their RR derivatives (Fig. 4a). Individual cells or those
growing in small clusters gained a more spindle-shaped
morphology with a larger amount of cytoplasm, with the
contact between cells now via focal points rather than cell
clusters. The MDA-MB-231 cell line already exhibited a
mesenchymal-like phenotype, and phenotypic changes in
its RR derivate were not obvious.
The observed change in cell morphology with the
acquisition of radioresistance is consistent with cells
undergoing EMT. We therefore investigated the expres-
sion levels of EMT markers using IHC for the MCF-7
and ZR-751 parental and RR cell lines and identified in-
creased expression of vimentin, N-cadherin and SNAIL,
along with the partial down regulation of E-cadherin in
the RR cell lines. The MDA-MB-231 cell line was char-
acterised by high vimentin along with low N-cadherin
and E-cadherin expression; no differences between paren-
tal and its RR derivative were identified (Fig. 4b and Add-
itional file 4: Figure S2 and Additional file 5: Figure S3).
These results were recapitulated using gene expression
analysis from a published EMT signature (Fig. 4c) [23].
This study combined bioinformatic expression data ana-
lysis from both The Cancer Genome Atlas and Cancer
Cell Line Encyclopaedia databases of seven tumour types
which identified a pan-cancer EMT-associated gene ex-
pression signature. The lists of genes used have been pro-
vided in Additional file 6: Table S3. In our analysis, the
MCF-7 and ZR-751 parental cell lines had a pattern of
expression consistent with an epithelial genotype, whereas
the MDA-MB-231 (both parental and RR) cells had higher
expression of the mesenchymal cluster of genes. The
MCF-7 RR and ZR-751 RR cell lines had a mixed
pattern of expression with relatively high expression
of both epithelial and mesenchymal genes, suggesting
a transition from an epithelial towards a mesenchymal
expression profile (Fig. 4c).
WNT signalling is increased in ER+ derived radioresistant
cell lines
Analysis of transcriptomic data from ER+ parental and
RR cell lines in respect of the WNT signalling pathway
was investigated due to its reputed role in EMT and
radioresistance [24]. The WNT pathway was investigated
using panels of WNT signalling pathway members and
down-stream targets, taken from the KEGG database
[25]. The lists of genes used have been given in Add-
itional file 6: Table S3. In this analysis the MCF7 RR and
ZR-751 RR cell lines had a pattern of expression consist-
ent with WNT pathway activation enriched for genes in-
cluding FRIZZLED family members 1/2/5/7, WNT5a
and WNT5b (Fig. 5a). IHC using MCF-7 and ZR-751
parental and RR MTS showed increased expression of
WNT5a in the radioresistant cell lines which was pre-
dominantly expressed in the cells located in the outer
proliferating layer of the MTS (Fig. 5b). Further valid-
ation through western blot analysis of serum starved
whole cell lysates (in accordance with gene analysis ex-
periments) also showed increased WNT5a expression in
the radioresistant cell lines at 0 and 24 h post-serum
starvation (Fig. 5c).
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Radioresistant MCF-7 and ZR-751 cell lines show loss of
ERα and PgR expression and gain in EGFR expression
Breast cancer subtypes can be characterised by the
expression profiles of key signalling receptors (ERα, PgR,
HER2 and EGFR). Western blotting and IHC showed
that the RR phenotype in the cell lines derived from ER+
cells was characterised by the loss of ERα and PgR ex-
pression, along with a gain in total EGFR expression
(Fig. 6A & B and Additional file 7: Figure S4 and Add-
itional file 8: Figure S5). ICC with quantitative analysis
Fig. 3 Radioresistant cell lines have increased invasion and migration potential. a 3D MTS invasion assays comparing MCF-7 RR, ZR-751 RR and
MDA-MB-231 RR MTS with their respective parental MTS. MTS were placed in collagen and invasion was assessed up to 120 h post-seeding. Area
of MTS at each time point was calculated and expressed as a % of initial MTS area at day 0. b 2D migration scratch assays comparing MCF-7 RR,
ZR-751 RR and MDA-MB-231 RR cell lines with their respective parental cells. Relative migratory distance was calculated at each time point and
expressed as a % area devoid of cells based on the initial scratched area at day 0 (2-way ANOVA with Holm-Sidak’s multiple comparisons test;
data expressed as mean ± SEM, n = 3, ****p ≤ 0.0001; ***p ≤ 0.001; **p ≤ 0.01)
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confirmed reduction in the percentage of cells stain-
ing positive for ERα expression in the MCF-7 RR
(0.27 ± 0.17%) cell line compared with the parental
MCF-7 cell line (81 ± 1.1%) and in the ZR-751 RR
(0.52 ± 0.36%) cell line compared with the parental
ZR-751 (96.5 ± 1.8%) cell line. No Staining was seen
in the MDA-MB-231 cell line or its RR derivative.
Three replicates with a minimum of 10 spheroids
were included in each analysis. To investigate the
consequences of this gain in EGFR expression, we
treated parental and RR cells with increasing doses of
the EGFR inhibitor, gefitinib, and determined its effect
on the proliferation and migration of ER+ parental
and RR cell lines. There was a statistically significant
Fig. 4 MCF-7 RR and ZR-751 RR cell lines show increased expression of vimentin, N-cadherin and SNAIL with the partial down regulation of E-
cadherin. a H&E staining of parental and RR cell lines detailing their morphological differences. b IHC staining of EMT markers (vimentin, N-cadherin,
SNAIL and E-cadherin) in MCF-7 and MDA-MB-231 parental and RR MTS and cells. c Heatmap showing log2 mean-centered gene expression profiles in
respect of a published cancer cell EMT-signature [23]; red = higher expression, green = lower. The gene list and the order in which they appear in the
heatmap are shown in Additional file 6: Table S3
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decrease in MCF-7 RR proliferation after 72 h with
gefitinib concentrations ranging from 0.1–15 μM com-
pared to the parental cell lines (IC50: MCF-7
13.36 μM, MCF-7 RR 6.43 μM) and a significant re-
duction in migration, with a dose of 5 μM decreasing
the migratory potential of the RR cell line to parental
levels (Fig. 6Ci & Cii). Similar results were also seen
in the ZR-751 parental and RR cell lines when treated
with gefitinib (Additional file 9: Figure S6). As we
had identified a loss in ERα expression, we also ex-
amined the effects of tamoxifen on the cell lines.
After 72 h of tamoxifen treatment there was a statisti-
cally significant increase in proliferation of the
MCF-7 RR cell line compared to the parental cell line
at concentrations ranging from 0.01–3 μM (Fig. 6Ciii).
ERα knockdown in MCF-7 cells results in EGFR
expression, reduction in proliferation and enhancement
of radiosensitivity
The loss of ERα in the MCF-7 cell line was further investi-
gated using ERα siRNA knockdown. ERα knockdown was
associated with increased EGFR expression 96 and 120
Fig. 5 WNT signalling is increased in ER+ derived radioresistant cell lines. a Heatmap showing log2 mean-centered gene expression profiles
between parental and RR cell lines in respect of the WNT signalling pathway (left heatmap) with selected WNT and FRIZZLED genes
shown (center) and WNT target genes (right), taken from the KEGG pathway database [25]; red = higher expression, green = lower
expression. The gene list and the order in which they appear in the heatmap are shown in Additional file 6: Table S3. Heatmap
clustering was carried out using Pearson correlation with average linkage. b IHC of WNT5a expression using MCF-7 and ZR-751 parental
and RR MTS. c Western blot analysis showing the levels of WNT5a in untreated MCF-7and ZR-751 cell lines in comparison to their RR
derivatives (samples were obtained at 0 and 24 h after a 2 h serum starve), (unpaired, two tailed t-test; data expressed as mean ± SEM,
n = 3, ****p ≤ 0.0001; ***p ≤ 0.001, ** p ≤ 0.01)
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Fig. 6 (See legend on next page.)
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h after transfection, as shown through western blot
analysis (Fig. 6D). There was also a significant reduc-
tion in proliferation of the MCF-7 cells after 72 h treat-
ment with either ERα siRNA (25 nM) or tamoxifen
(0.05 μM) (Fig. 6Ei), whereas no reduction in prolifera-
tion was seen in the MCF-7 RR cells (6Eii). An add-
itional reduction in MCF-7 proliferation was observed
when ERα knockdown or tamoxifen treatment was com-
bined with radiation 24 h after transfection/tamoxifen
treatment (Fig. 6Fi&ii), suggesting a radiosensitising rather
than a radioprotective effect from ERα loss.
Radioresistant cell lines exhibit cellular plasticity within
the context of intrinsic breast cancer subtyping
ER signalling was further investigated through the appli-
cation of a published gene expression signature for ER
pathway signalling activity to our transcriptomic data
[26]. As expected, the ER+ parental cell lines (MCF-7
and ZR-751) were characterised by high expression of
these genes whereas the ER- parental and RR cell lines
(MDA-MB-231) had lower expression. Interestingly, the
MCF-7 RR and ZR-751 RR cells clustered with the ER-
cell lines in hierarchical clustering analysis, although
they maintained higher expression levels, similar to their
parental cells, for a subset of these genes. Treatment
with 2 Gy of radiation for 2 and 8 h was not found to in-
fluence the expression of these genes (Fig. 7a).
Gene expression data was integrated with a public
gene expression dataset (GSE50811) of 67 breast
cancer cell lines. The MDA-MB-231 parental and RR
cell lines, both treated and untreated, clustered
tightly with each other in the dendrogram branch
enriched for the basal breast cancer subtype. Both
treated and untreated MCF-7 and ZR-75-1 parental
cell lines were classified as luminal A whereas their
RR derivates clustered independently and were
enriched for normal-like (ZR-751 RR) and HER2-overex-
pressing (MCF-7 RR) intrinsic subtypes (Fig. 7b and Add-
itional file 10: Figure S7).
PI3K and MAPK activity are increased in ER+ derived
radioresistant cell lines
Downstream signal transduction pathways of the HER/
ERBB tyrosine-kinase receptor family were further
investigated following identification that total EGFR ex-
pression was increased in the ER+ derived RR cell lines.
Western blot analysis of time course experiments up to
30min after 2 Gy radiation showed increased levels of
p-ERK in MCF-7 RR and ZR-751 RR cell lines 5 min
post-radiation, whereas a smaller increase was seen in
the parental cell lines at a later time point (Fig. 8a). Al-
though p-AKT did not show increased levels in response
to radiation, the RR cell lines had overall increased ex-
pression levels compared with the parental cell lines
(Fig. 8b). No differences were seen in the MDA-MB-231
and RR cell lines. The activity of the MAPK pathway in
our cell lines was investigated using a published gene ex-
pression signature [27]. PI3K activity was assessed using
genes taken from the KEGG pathway database [25] in
combination with FOXO-regulated genes (these have an
inverse expression pattern to PI3K activity) [28]. Gene ex-
pression analysis suggested that active MAPK and inactive
PI3K signalling were constitutive in the MDA-MB-231
parental and RR cell lines and expression levels of these
signalling pathways were not affected by radiation treat-
ment. The untreated ER+ cell lines were characterised
by both inactive MAPK and PI3K activity, whereas their
RR derivatives had lower overall expression of the
MAPK-associated genes, potentially representing a switch
to active MAPK and PI3K signalling (Fig. 8c and d).
Discussion
Intrinsic or acquired radioresistance can be a significant
obstacle in the treatment of many cancers, including
breast. In this study we developed novel radioresistant
cell lines from both ER+ and ER- breast cancer cell lines
and characterised their inherent differences and re-
sponses to radiation through genetic, molecular and cell
biology approaches. Radioresistance was acquired in all
3 RR cell lines, which validated their use as an in vitro
model system to help characterise this phenotype and
investigate the mechanisms involved in radioresistance
development and treatment failures in patients. The
radioresistant phenotype was also shown to be main-
tained in MCF-7 RR cells that were not exposed to radi-
ation for 6 months indicating that the acquisition of
radioresistance is not transient. This has important
therapeutic implications and is in contrast to a previous
(See figure on previous page.)
Fig. 6 Radioresistant MCF-7 and ZR-751 cells show loss of ERα and PgR expression and gain in EGFR expression with a shift from ER to EGFR
signalling pathways. A and B Expression profiles of signalling receptors, ERα, PgR, Her2 and EGFR in MCF-7 and MCF-7 RR cell lines using A IHC
with MTS and B Western blot analysis. Ci SRB at 72 h and Cii scratch assay at 24 and 48 h showing the effects of the gefitinib in MCF-7 and RR
cell lines. Ciii SRB assay showing the effect of tamoxifen in MCF-7 and RR cell lines at 72 h. D Levels of EGFR expression increased 96 and 120 h
after ERα siRNA knockdown. Graphs document the relative intensity of EGFR normalised to the loading controls using 25 nM of ERα siRNA. Ei&ii
SRB assay showing significant reduction in proliferation of the MCF-7 cells after 72 h treatment with either ERα siRNA (25 nM) or tamoxifen
(0.05 μM), whereas no reduction in proliferation was seen in MCF-7 RR cells. Fi&ii SRB assay showing an additional reduction in MCF-7 proliferation
following ERα knockdown or tamoxifen treatment when combined with radiation 24 h after transfection/tamoxifen treatment (2-way ANOVA with
Holm-Sidak’s multiple comparisons test; data expressed as mean ± SEM, n = 3, ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05)
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study that showed radioresistant MCF-7 cells lost their
resistant phenotype 12 weeks after a final dose of radi-
ation [29]. The difference in maintenance of the RR
phenotype could be due to our cell lines being exposed
to radiation over a longer time period, which could con-
tribute to more stable phenotypic changes and highlights
the importance of performing regular CF/SRB assays to
confirm the maintenance of radioresistance.
Only a small number of other studies have investigated
mechanisms of acquired RR through the generation of
RR cell lines, which tend to focus on a single specific
pathway [7, 29–33]. Reduced proliferation rates have
been identified in RR cell lines [34]; reduced prolifera-
tion in our MCF-7 RR and ZR-751 RR cell lines was
reflected in the gene expression profiles and reduced
Ki67 expression in MTS. One study used 3 prostate can-
cer cell lines (androgen responsive and non-responsive)
to develop RR derivates; they identified enhanced EMT/
cancer stem cell phenotypes and activation of check-
point proteins and PI3K/AKT/mTOR signalling
pathways in the RR cells [31]. Our study took a similar
approach by using 3 breast cancer cell lines, 2 ER+ and
hormone responsive (MCF-7 and ZR-751) and 1 ER-
and hormone non-responsive (MDA-MB-231). However,
our approach was more global and investigated multiple
potential radioresistance mechanisms rather than focus-
ing on individual pathways.
Among breast cancer patients, more than 90% of
cancer related deaths are from metastatic rather than
primary disease [35]; further understanding of breast
cancer metastasis and treatment failure is therefore of
clinical importance. We identified that the MCF-7 RR
and ZR-751 RR cell lines had increased invasion and
migration ability compared with their parental cell
lines whereas the MDA-MB-231 RR cell line exhibited
increased migration but had only a marginal, non-sig-
nificant increase in invasion compared to the parental
cells. The results suggest that these RR cell lines de-
veloped a more aggressive phenotype, which was
more pronounced in the ER+ derived RR cell lines,
Fig. 7 ER+ derived radioresistant cell lines exhibited a change in oestrogen signalling associated genes and a change in intrinsic breast cancer
subtyping. a Heatmap showing log2 mean-centered expression profile of a published oestrogen-signalling gene signature [26]; red = higher
expression, green = lower expression. Heatmap clustering was carried out using Pearson correlation with average linkage. b Study data was
integrated with a public gene expression dataset (GSE50811) of 67 breast cancer cell lines. Hierarchical clustering of parental and RR cell lines
based on Pearson correlation to centroids of Sørlie 2003 intrinsic genes [16]; Red = Basal, Dark blue = Luminal A, Light blue = Luminal B,
Purple = HER2-overexpressing, Green = Normal-like
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which clinically could lead to a greater potential for
metastasis.
To model this further we used well established MTS
models that more accurately represent the tumour
microenvironment within a solid tumour; MTS ex-
hibit 3D cell-cell interactions and can develop O2, nutri-
ent and catabolite gradients, producing a central
necrotic core and outer proliferating layer of cells [36].
The novel MTS derived from RR cells developed in this
study serve as excellent tumour models of radioresis-
tance to investigate invasiveness and protein expression
through IHC, which aided in their classification.
EMT is an important process in malignant transform-
ation that leads to reduced cell–cell contacts, increased
cell motility and metastasis [37–39]. Loss of epithelial
morphology is an important prognostic indicator that
Fig. 8 Activation of PI3K and MAPK pathways in ER+ derived radioresistant cell lines. a and c MAPK pathway activity; b and d PI3K pathway
activity. a Western blot analysis showing the levels of p-ERK in response to a single fractionated dose of 2 Gy radiation in MCF-7, ZR-751 and
MDA-MB-231 cell lines in comparison to their RR derivatives. b Western blot analysis showing the levels of p-AKT in response to a single
fractionated dose of 2 Gy radiation in MCF-7, ZR-751 and MDA-MB-231 cell lines in comparison to their RR derivatives (2-way ANOVA with Holm-
Sidak’s multiple comparisons test; data expressed as mean ± SEM, n = 3, ****p ≤ 0.0001; *p ≤ 0.05). c Heatmap showing log2 mean-centered gene
expression profiles between parental and RR cell lines in respect to a MAPK pathway activity gene signature [27]. d Heatmap showing log2
mean-centered gene expression profiles between parental and RR cell lines in respect of the PI3K pathway (associated genes taken from the PI3K
KEGG pathway (upper heatmap) and FOXO-regulated genes (lower heatmap) [28]. Heatmap clustering was carried out using Pearson correlation
with average linkage
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correlates with worse prognosis [40]. Hybrid/intermedi-
ate phenotypes show the ability of cancer cells to
undergo EMT and mesenchymal-to-epithelial-transition,
thus traversing the epithelial and mesenchymal states
[38]. In our RR model we demonstrated a down regula-
tion of E-cadherin and upregulation of vimentin,
N-cadherin and SNAIL, all known biomarkers for EMT
in breast cancer [41], in the MCF-7 RR and ZR-751 RR
cell lines. These results support the morphological and
functional changes in RR cells, which developed a more
mesenchymal-like phenotype with increased invasive
and migratory potential. The MDA-MB-231 cell line has
previously been characterised as having a mesenchymal-
like phenotype with constitutively low E-cadherin and
high vimentin expression, so any further development of
EMT in its RR derivative was difficult to ascertain. Many
signalling pathways can activate EMT in both normal
and cancer cells, including receptor tyrosine kinase sig-
nalling, TGFβ, Wnt-β-catenin and Notch signalling [42,
43]; radiation alone can also induce EMT through the
expression of TGFβ [44, 45]. Both EGFR downstream
signalling pathways and Wnt signalling were found to be
activated in our MCF-7 RR and ZR-751 RR cell lines
suggesting possible mechanisms by which the cells
underwent EMT. It is interesting to note that the same
population of cells, predominantly those around the per-
iphery of the MTS formed from ER+ RR cells, showed
increased co-expression of vimentin, Snail, N-cadherin
and WNT5a.
Breast cancer is routinely characterised immunohisto-
chemically by the expression of receptors such as HER2,
ERα, PgR and EGFR; gene expression profiling can also
be used to identify molecular characteristics of breast
cancer cells and classify them into 5 specific subtypes
with distinct clinical outcomes: luminal A, luminal B,
HER2-overexpressing, basal and normal-like tumours
[46, 47]. These different breast cancer subtypes have also
been shown to exhibit differential inherent sensitivities
to ionising radiation and reflect prognosis [48, 49]. The
clinical usefulness of molecular subtyping of cell lines
has been previously investigated through comparing the
genomic and transcriptional characteristics of breast
cancer cell lines with that of primary breast tumours.
One study showed that recurrent genome aberrations
and the resulting transcriptional changes identified in 51
cell lines (including MDA-MB-231, MCF-7 and ZR-751)
were well preserved in comparison to those found in pri-
mary tumours of a similar classification and that cell
lines may not accumulate substantial new mutations
during extended culture, showing stable genomic pat-
terns over multiple passages [50]. Although the cell lines
carried more genome aberrations, possibly related to
some cell lines having been derived from late stage tu-
mours or pleural effusions, they concluded that cell lines
were well suited to assess the functional consequences
of genome-aberrations-mediated gene deregulation and
to identify molecular features that predict resistance/
sensitivity to agents targeting these aberrations. How-
ever, it is important to note that cell line expression pro-
files will not account for the tumour microenvironment
including normal epithelial cells or stromal tissue, nor
will they reflect intra-tumoural heterogeneity. With
these caveats in mind the purpose of subtyping in this
study was to demonstrate that the development of radio-
resistance is consistent with a change to a prognostically
less favourable intrinsic subtype.
In our study the transcriptional profiles of parental
and RR cell lines were assigned to intrinsic breast cancer
subtypes. Both the MDA-MB-231 parental and RR cell
lines were triple negative, and subtyping identified them
as basal [16, 46, 51, 52]. As the MDA-MB-231 parental
cell line is inherently aggressive, it is not surprising that
no significant changes were identified in its RR deriva-
tive. However, a change in classification was identified
in RR cell lines derived from ER+ cells, with a shift
from luminal A for both MCF-7 and ZR-751 cell lines
towards a non-luminal classification. The MCF-7 RR
cell line was most closely correlated to the HER2-over-
expressing subtype while the ZR-751 RR cell line was
more closely correlated to the normal-like subtype.
Both HER2-overexpressing and normal-like subtypes
carry a worse prognosis compared to luminal A tu-
mours, with HER2-overexpressing tumours having a
higher risk of locoregional recurrence [16, 46, 51, 52].
Luminal A tumours also respond well to hormone and
radiation treatment [51], and a shift away from this
subtype would therefore be consistent with a loss of ra-
diosensitivity, resistance to endocrine therapy and a
more aggressive phenotype. These results show that the
acquisition of radioresistance can be linked with cellu-
lar plasticity through extensive alterations in gene ex-
pression resulting in a change in molecular subtype.
Analysis of protein expression indicated that both
MCF-7 RR and ZR-751 RR cell lines lost both ERα and
PgR expression and gained EGFR expression. Further-
more, ERα siRNA knockdown resulted in increased
EGFR protein expression in the MCF-7 cell line, suggest-
ing a direct relationship between loss of ERα and in-
creased EGFR expression. Using gene analysis, we
further identified that ER driven genes had lower expres-
sion in the RR cell lines derived from ER+ cell lines. An
inverse relationship between ER activity and EGFR and
HER2 expression has been reported in clinical breast
cancer, with overexpression of these receptor tyrosine ki-
nases being associated with decreased sensitivity to
endocrine therapy and a poorer prognosis [53–55]. An
apparent switch from ER signalling to EGFR-mediated
signalling was investigated by the treatment of MCF-7
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and MCF-7 RR cells with the EGFR inhibitor gefitinib
and the anti-oestrogen tamoxifen.
Gefitinib produced a greater concentration-dependent
reduction in cell proliferation in the MCF-7 RR cell line
with an IC50 value of 6.43 μM. This is a relatively high con-
centration compared to clinically relevant doses [56–58];
however, while this suggests the MCF-7 RR cell line is rela-
tively insensitive to the effects of gefitinib, there was a sig-
nificant reduction in the IC50 value from 13.34 μM for the
MCF-7 parental cell line. Results also showed that the RR
cells developed simultaneous resistance to tamoxifen at
clinically relevant doses. Tamoxifen may be given to pa-
tients with ER+ breast cancer for 3–5 years following sur-
gery and radiotherapy; if radioresistant cells remain
following a patient’s RT course then the efficacy of tamoxi-
fen in radioresistant cells needs to be assessed. Mecha-
nisms for acquired tamoxifen resistance are complex since
tamoxifen resistant tumours usually do not lose ERα [59],
with the receptor still remaining functional as demon-
strated by cohorts of patients with recurrent disease
still being able to respond to secondary endocrine ther-
apy [60, 61]. This has led to studies suggesting that
tamoxifen resistance is through modification of ER
functionality by growth factor pathways [62, 63]. A pre-
vious study using MCF-7 RR cells demonstrated resist-
ance to tamoxifen without a change in ER expression.
However, AKT phosphorylation was increased and the
investigators suggested that sequential tamoxifen treat-
ment following radiation could be more effective than
concurrent treatment [33]. Conversely, results from our
study showed that when radiation was delivered 24 h
after tamoxifen treatment or ERα knockdown in the
MCF-7 cells, an additional decrease in proliferation was
observed, suggesting that the use of tamoxifen before and
during a patient’s RT treatment may be advantageous. An-
other study determined that tamoxifen-resistant MCF-7
cells, showed enhanced sensitivity to EGF and oestradiol
stimulation. Although ERα was not lost, it was found to
redistribute to extra-nuclear sites (cytoplasmic transloca-
tion) in the tamoxifen-resistant cells and they suggested
that enhanced ERα function, via cooperation with EGFR,
is one mechanism responsible for acquired tamoxifen re-
sistance [64]. Similar results have also been shown with
the establishment of anti-oestrogen-resistant MCF-7 cells,
developed through continuous culture in fulvestrant
(trade name Faslodex). These resistant cells developed re-
duced ERα expression and loss of PgR with increased de-
pendence on EGFR/MAPK mediated signalling [65]. Our
radioresistant model has shown that ERα and PgR loss oc-
curs with concurrent resistance to tamoxifen which may
involve different pathways compared to the development
of tamoxifen resistance from chronic drug exposure. This
suggests that additional targeted therapy may be required
in these cells.
Because total EGFR expression was significantly in-
creased in the RR cell lines, the downstream signal
transduction pathways of the HER tyrosine-kinase recep-
tor family were further investigated.
The phosphatidylinositol-3-kinase (PI3-k)/protein kin-
ase B (AKT) cascade is frequently overactive in a wide
range of cancers and can trigger a cascade of responses re-
lated to cell survival and metabolism [66, 67]. It is also ac-
tivated by RT and has been associated with resistance
mechanisms such as intrinsic radioresistance, tumour cell
proliferation and hypoxia [68, 69]. In this study we found
that the gene expression signature in the MCF-7 RR and
ZR-751 RR cell lines fitted with activation of the PI3K
pathway. Although p-AKT did not increase in response to
radiation, its levels were statistically higher than in the
parental derivatives, suggesting that the PI3K/AKT/
mTOR signalling pathway is activated in these RR cell
lines and may play an important role in radioresistance.
In breast and other cancers radiation-induced prolifera-
tion has been linked with activation of EGFR and down-
stream components of the mitogen-activated protein kinase
(MAPK) cascade, including phospholipase-C, Ras, and
Raf-1 [70–73] and can be considered an important cytopro-
tective response [74]. MAKP activation may represent a
mechanism by which cancer cells can cause tumour re-
population during fractionated RT courses. Results from
this study at the gene and protein level suggest that MAPK
signalling is activated in the MCF-7 RR and ZR-751 RR cell
lines since basal levels of p-ERK1 and p-ERK2 were
significantly higher than in their parental cell lines
and phosphorylation of ERK1 and ERK2 occurred al-
most immediately following a 2 Gy radiation dose. This
radiation-induced phosphorylation occurred more quickly
and to a larger extent than in the parental cell lines. Our
results suggest that EGFR signalling, and multiple compo-
nents of its downstream pathways are activated in the
MCF-7 RR and ZR-751 RR cell lines, which could have
significant clinical implications, as multiple pathways may
need to be targeted to improve the therapeutic response
to irradiation.
The use of multiple techniques ranging from gene to
protein to functional experiments, which led to the val-
idation of our results through independent means, rep-
resents one of the main strengths of this study.
Additionally, the development of ER+ and ER- RR cell
lines allowed for comparisons to be made between dif-
ferent molecular breast cancer subtypes. The aim of our
study was to characterise these RR cell lines and identify
pathways that could be related to radioresistance, rather
than focusing on the reversal of radioresistance itself.
However, following our successful characterisation, we
now aim to use these cell lines in future studies to target
these identified pathways and to identify biomarkers
(genetic and secretomic signatures) that could be used
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for determining radiosensitivity and for the assessment
of a tumour’s response to radiotherapy.
Conclusion
In this study we developed a novel model to help improve
the understanding and characterisation of radioresistant
breast cancer cells and identified several important and
likely interrelated networks contributing to the develop-
ment of radioresistance. ER+ derived RR cell lines were
characterised by a shift towards a more invasive mesen-
chymal phenotype with changes in oestrogen regulation,
gain of EGFR signalling and change in subtype classifica-
tion. The ER- cell line possessed these characteristics at
the outset and hence its phenotype changed relatively little
with the development of radioresistance. Here we have
begun to dissect the mechanisms and signalling pathways
involved in the development of radioresistance. Models of
resistant disease as developed and examined in this study
will be instrumental in future research and will aid the de-
velopment of new therapeutic strategies for patients that
either fail to respond or develop recurrent disease.
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